2024
Lifetime prevalence, comorbidities, and Sociodemographic predictors of post-traumatic stress disorder (PTSD): the National Epidemiology of Iranian Children and adolescents Psychiatric disorders (IRCAP)
Hooshyari Z, Mohammadi M, Salmanian M, Ahmadi N, Khaleghi A, Garakani A. Lifetime prevalence, comorbidities, and Sociodemographic predictors of post-traumatic stress disorder (PTSD): the National Epidemiology of Iranian Children and adolescents Psychiatric disorders (IRCAP). European Child & Adolescent Psychiatry 2024, 33: 3965-3978. PMID: 38656607, DOI: 10.1007/s00787-024-02441-7.Peer-Reviewed Original ResearchPrevalence of post-traumatic stress disorderPost-traumatic stress disorderTraumatic eventsAnxiety disordersStress disorderPsychiatric disordersSchool-Age Children-Present and Lifetime VersionKiddie Schedule for Affective DisordersSchedule for Affective DisordersLifetime prevalenceLifetime prevalence of post-traumatic stress disorderType of traumatic eventPredictors of post-traumatic stress disorderRates of PTSDSeparation anxiety disorderGeneralized anxiety disorderK-SADS-PLOppositional defiant disorderPrevalence of PTSDRates of comorbidityAdolescent psychiatric disordersLifetime prevalence ratesPrevalence rates of comorbiditiesDepressive disorderLifetime VersionAntipsychotic agents in anxiety disorders: An umbrella review
Garakani A, Buono F, Salehi M, Funaro M, Klimowicz A, Sharma H, Faria C, Larkin K, Freire R. Antipsychotic agents in anxiety disorders: An umbrella review. Acta Psychiatrica Scandinavica 2024, 149: 295-312. PMID: 38382649, DOI: 10.1111/acps.13669.Peer-Reviewed Original ResearchSecond-generation antipsychoticsFirst-generation antipsychoticsGeneralized anxiety disorderStudies of antipsychoticsAnxiety disordersAntipsychotic agentsEfficacy of first-generation antipsychoticsTreatment of anxiety disordersEfficacy of antipsychotic agentsMeta-analysesAntidepressant treatmentNonantipsychotic medicationsAntipsychoticsFirst-line treatmentAnxietyComparing monotherapyUmbrella reviewDisordersQuetiapineSystematic reviewSide effectsAMSTAR-2Off-labelAPA PsycInfoCINAHL Complete
2022
An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol
Garakani A, Freire RC, Buono FD, Thom RP, Larkin K, Funaro MC, Salehi M, Perez-Rodriguez MM. An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol. PLOS ONE 2022, 17: e0269772. PMID: 35709149, PMCID: PMC9202921, DOI: 10.1371/journal.pone.0269772.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsSerotonin-norepinephrine reuptake inhibitorsUse of antipsychoticsLong-term riskAnxiety disordersReuptake inhibitorsUmbrella reviewSide effectsPanic disorderSystematic reviewNon-antipsychotic medicationsUse of quetiapineFirst-line treatmentSerotonin reuptake inhibitorsNorepinephrine reuptake inhibitorsEvidence of efficacyCommon psychiatric disordersTraditional pharmacologic treatmentTreatment of anxietyAdjunctive treatmentPharmacologic treatmentTricyclic antidepressantsAntipsychoticsPsychiatric disordersSocial anxiety disorder
2021
Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough?
Thom RP, Alexander JL, Baron D, Garakani A, Gross L, Pine JH, Radhakrishnan R, Slaby A, Sumner CR. Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough? Journal Of Psychiatric Practice 2021, 27: 361-371. PMID: 34529602, DOI: 10.1097/pra.0000000000000578.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsLong-term SSRI useSSRI useEase of titrationFirst-line medicationSerotonin reuptake inhibitorsRisk-benefit ratioMajor depressive disorderGeneral health risksShort-term useClinical practice considerationsDiscontinuation syndromeReuptake inhibitorsSafety profileDepressive disorderPatientsPsychiatric conditionsRelapse preventionMedicationsPossible adverse consequencesSpecial populationsAnxiety disordersTolerabilityPrescribersAdverse consequencesPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. FOCUS The Journal Of Lifelong Learning In Psychiatry 2021, 19: 222-242. PMID: 34690588, PMCID: PMC8475923, DOI: 10.1176/appi.focus.19203.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTreatment optionsAnxiety disorders
2020
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers In Psychiatry 2020, 11: 595584. PMID: 33424664, PMCID: PMC7786299, DOI: 10.3389/fpsyt.2020.595584.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsPosttraumatic stress disorderAnxiety disordersGABAergic medicationsReuptake inhibitorsRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialPanic disorderStress disorderSpecific phobiaBeta-adrenergic medicationsPlacebo-controlled trialCurrent pharmacological treatmentsNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsCause of disabilityPrevalent psychiatric disordersNovel pharmacotherapeutic agentsBeta-adrenergic agentsSocial anxiety disorderMixed antidepressantsGlutamate modulatorsGlutamatergic agentsObsessive-compulsive disorder
2014
Advances in Psychopharmacology for Anxiety Disorders
Garakani A, Murrough J, Iosifescu D. Advances in Psychopharmacology for Anxiety Disorders. FOCUS The Journal Of Lifelong Learning In Psychiatry 2014, 12: 152-162. DOI: 10.1176/appi.focus.12.2.152.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsPosttraumatic stress disorderAnxiety disordersReuptake inhibitorsRelated conditionsGamma-aminobutyric acid (GABA) systemPharmacological treatment modalitiesFirst-line treatmentSerotonin reuptake inhibitorsNew pharmacotherapeutic approachesNorepinephrine reuptake inhibitorsVasopressin receptor antagonistsNovel treatment optionsPrevalent psychiatric disordersGlutamate modulatorsMedication classesCertain anxiety disordersNeuropeptide YTreatment modalitiesTreatment optionsNew drug developmentReceptor antagonistNew medicationsPharmacotherapeutic approaches
2010
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonists
2008
Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study
Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donahue S. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study. Clinical Therapeutics 2008, 30: 1658-1666. PMID: 18840371, DOI: 10.1016/j.clinthera.2008.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Anxiety AgentsAnxiety DisordersDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleFemaleHumansMaleMiddle AgedPiperazinesPsychiatric Status Rating ScalesSerotonin 5-HT1 Receptor AgonistsSerotonin Receptor AgonistsSingle-Blind MethodSulfonamidesSurveys and QuestionnairesTreatment OutcomeConceptsGeneralized anxiety disorderShort-term tolerabilityAdverse eventsPRX-00023Hamilton Anxiety Rating Scale scoresVital signsResponse criteriaAnxiety disordersTotal scoreOpen-label studySerotonin 1A agonistSingle-blind placeboAnxiety Rating Scale scoresSerious adverse eventsStudy end pointInfluenza-like symptomsOpen-label treatmentPrimary outcome measureDiagnosis of GADRating Scale scoresEnd point changeSample of patientsSerotonin 1A receptorPremature ventricular contractionsSelective partial agonist
2006
Neurobiology of anxiety disorders and implications for treatment.
Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatment. Annals Of Global Health 2006, 73: 941-9. PMID: 17195879.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPost-traumatic stress disorderCognitive behavioral therapyFear conditioningUnconditioned stimulusAnxiety disordersPartial NMDA agonistFear inhibitionFear extinctionTraumatic memoriesFear circuitryFear responsesPavlovian conditioningBehavioral therapyStress disorderSpecific phobiaNew learningAmygdala pathwayD-cycloserineAnti-anxiety treatmentPanic disorderPreliminary evidenceStimuliMemoryN-methyl-D-aspartate antagonistsNeurobiology
2003
Comorbidity of Irritable Bowel Syndrome in Psychiatric Patients: A Review
Garakani A, Win T, Virk S, Gupta S, Kaplan D, Masand PS. Comorbidity of Irritable Bowel Syndrome in Psychiatric Patients: A Review. American Journal Of Therapeutics 2003, 10: 61-67. PMID: 12522523, DOI: 10.1097/00045391-200301000-00014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIrritable bowel syndromePsychiatric patientsBowel syndromeChronic abdominal discomfortFunctional gastrointestinal disordersU.S. adult populationStool frequencyAbdominal bloatingAbdominal discomfortPresence of mucusGastrointestinal disordersPsychiatric comorbidityMajor depressionHigh prevalencePanic disorderPatientsAdult populationComorbiditiesAnxiety disordersSyndromeDisordersPrevalenceTreatmentRecent studiesBloating